Table 1.
Characteristics of included studies and quality assessment.
| Author/ Year | Country | Treatment focus | Number of participants | Type of participants | Methods |
|---|---|---|---|---|---|
| Lu CY et al./ 2007 | 1 Country/(Australia) | Anti-rheumatology biologicals | 36 | Rheumatologist, patients with RA, government advisors, consumer advocates, public servant and pharmaceutical company spokesperson | Semi structured interview (in-depth interview), purposeful sampling |
| Jakub Adamski et al./ 2010 | 15 countries/(Sweden, Italy, UK, Germany, Estonia, USA, France, Spain, Lithuania, Australia, Belgium, Hungary, Portugal, Canada, Denmark) | Any | 16 | Health Authority Personnel from 14 different countries. | Literature review and combined knowledge of the personnel |
| Espin J. et al./ 2011 | 18 Countries (Austria, Denmark, Finland, Iceland, Ireland, Italy, Lithuania, Malta, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, UK) | Oncology | 19 | Members of the Network Meetings of the Competent Authorities on Pricing and Reimbursement EU and EFTA countries | Online Survey(First – on Oncology products and Second on one Risk Sharing Scheme in each country) |
| Sabine Vogler et al./ 2012 | 20 EU Member states and 6 non-EU | Any | 26 | Members of PPRI member network (Medicines Agency and Ministry of Health) | Open ended questionnaire sent via e-mail and review of information |
| Lisbet Coulton et al./ 2012 | Australia, Taiwan, Indonesia, Singapore, Mainland China, Philippines, Malaysia, South Korea, Thailand | Any | 14 | Expert panel; Consultants, Academics, Researcher, NGOs, Pharma personnel | Review of information, Expert panel discussion and detailed questionnaire |
| Ariel Hammerman et al./ 2012 | Israel | Any | 31 | Government Official, Senior Managers of Health Plan, pharmaceutical industry executive, academic researchers, Non-Governmental organization | Semi-structured questionnaire, face to face interview, audio record and transcribed verbatim, Purposive sampling |
| Paige A. Thompson/ 2012 | Canada | Any | 9 | Drug Plan Managers – Canadian Provincial Government representatives | Literature review and key informant interview using semi-structured questionnaire via telephone, Purposive sampling |
| Steve G. Morgan et al./ 2013 | Canada | Any | 9 | Senior Executive of Health plan | Semi-structured questionnaire, Telephone interviews with purposefully selected individuals |
| Louis. P Garrison et al./ 2015 | U.S | Any- Private sector | 14 (interview), 15 (online survey) | Pharmaceutical company, Payer organization and industry experts | Review of database, Key informant interview – in-depth 1 h telephone interview and online survey. Purposive sampling |
| Melissa Thompson et al./ 2016 | Canada | Any | 21 | HTA key opinion leaders, pharmaceutical industry chief executive officer/vice presidents, ex-payers, current payer/drug plan managers | Telephone or in-person interviews (5-questions version or a 16-questions version) |
| Arvind Mani et al./ 2016 | Canada | Any – Private Sector | 30 | Pharmaceutical companies and payer representatives | Online survey |
| Taza Nazareth et al./ 2017 | US, France, Germany, Italy, Spain, UK | Any | 27 | Senior experts from US and EU-5 national payer, pharmaceutical manufacturer, pricing and market access executive | Structured interview with targeted literature review. Telephone interview with senior experts (1hr) |
| Kim Pauwels et al. / 2017 | Belgium, the Netherlands, Scotland, England & Wales, Sweden, Italy, Czech Republic, France | Oncology | Not stated | Authorities involved in set-up and negotiation of Managed Entry Agreements and PPRI network members | Literature search & document analysis, Semi-structured interview via telephone and audio recorded and verbatim |
| Steve. G Morgan et al./ 2017 | 11 developed countries (Australia, Austria, Canada, England, Germany, New Zealand, Norway, Scotland, Sweden, the Netherlands, USA) | Any | 10 | Public or social health systems – Manager & technical experts | Anonymous online survey |
| Joseph A. Goble et al./ 2017 | US | Any | 32 responses (web-survey) | Payer Medical and Pharmacy Directors | 37 item questionnaire, web-survey |
| Alessandra Ferrario et al./ 2017 | 16 (Latvia, Poland, Bosnia & Herzegovina, Hungary, Slovenia, Lithuania, Albania, Kosovo, Estonia, Romania, Russia, Serbia, Bulgaria, Poland, Slovakia, Croatia, Czech) | Any | 16 | Senior staff in competent authorities for pricing and reimbursement, academics with expertise on National pharmaceutical issues, national experts in pharmaceutical matters, Members of Piperska group | Questionnaire Survey send to informants |
| William C.N. Dunlop et al./ 2018 | France, Germany, Italy, Spain, the UK | Any | 66 | Hospital pharmacist with procurement responsibility, current or former members of regional or national healthcare payer or budget-setting organisations | Online survey (web based with closed, multiple choice questions) for stakeholder |
| Christiane Maskineh et al./ 2018 | Middle eastern and northern African region (Algeria, Egypt, Lebanon, Jordan, United Arab Emirates (UAE), Kingdom of Saudi Arabia (KSA)) | Any | 44 | Public sector, pharmaceutical industry | Prospective, cross-sectional, mailed online survey |
| Jacoline C. Bouvy et al./ 2018 | Europe (Spain, Italy, Germany, France, Austria, UK, Norway, Sweden, the Netherlands) | Any | Semi-structured interview – 17 Questionnaire – 13 Workshop − 30 |
Manufacturer, payer, HTA agency personnel | Semi-structured questionnaire (face to face or telephone) and questionnaire to identify status of products. Results discussion during workshop |
| Alexandru M. Rotar et al./ 2018 | 6 (Bulgaria, Croatia, the Czech Republic, Hungary, Poland, Romania) | Any | 10 | Country Experts | Questionnaire and extended phone calls |